PMID- 28447760
OWN - NLM
STAT- MEDLINE
DCOM- 20180220
LR  - 20211204
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 15
IP  - 5
DP  - 2017 May
TI  - Expression of mTOR/70S6K signaling pathway in pathological scar fibroblasts and 
      the effects of resveratrol intervention.
PG  - 2546-2550
LID - 10.3892/mmr.2017.6339 [doi]
AB  - The aim of the study was to examine the expression of mammalian target of 
      rapamycin (mTOR)/70S6K signaling pathway in pathological scar fibroblasts and the 
      effects of resveratrol (Res) intervention. The mTOR and 70S6K in pathological 
      scar and normal skin fibroblasts were detected by immunofluorescence following 
      treatment with different concentrations of Res. RT-PCR and western blot analysis 
      were used to detect the expression of mTOR and 70S6K mRNA and protein, 
      respectively. Immunofluorescence showed that the expression of 70S6K and mTOR was 
      significantly enhanced in pathological scar fibroblasts, and mainly expressed in 
      the nucleus, but not in normal skin fibroblasts. RT-PCR and western blot analysis 
      showed that after different concentrations of Res treatments, the mTOR and 70S6K 
      mRNA and protein expression significantly (P<0.05) decreased in a dose‑dependent 
      manner. In conclusion, the expression of mTOR/70S6K signaling pathway in 
      pathological scar fibroblasts was significantly enhanced. Res can downregulate 
      the expression of mTOR and 70S6K to achieve the inhibition of pathological scar 
      fibroblast proliferation.
FAU - Tang, Zhi-Ming
AU  - Tang ZM
AD  - Department of Dermatology, Xuzhou Hospital of Traditional Chinese Medicine, 
      Xuzhou, Jiangsu 221003, P.R. China.
FAU - Zhai, Xiao-Xiang
AU  - Zhai XX
AD  - Department of Dermatology, Xuzhou Hospital of Traditional Chinese Medicine, 
      Xuzhou, Jiangsu 221003, P.R. China.
FAU - Ding, Ji-Cun
AU  - Ding JC
AD  - Department of Burns and Plastic Surgery, The Affiliated Xuzhou Center Hospital of 
      Nanjing University of Chinese Medicine, Xuzhou, Jiangsu 221009, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170316
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Stilbenes)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Ribosomal Protein S6 Kinases, 70-kDa)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Cicatrix/drug therapy/*enzymology
MH  - Female
MH  - Fibroblasts/*enzymology/pathology
MH  - Gene Expression Regulation, Enzymologic/*drug effects
MH  - Humans
MH  - Male
MH  - Resveratrol
MH  - Ribosomal Protein S6 Kinases, 70-kDa/*biosynthesis
MH  - Signal Transduction/*drug effects
MH  - Stilbenes/*pharmacology
MH  - TOR Serine-Threonine Kinases/*biosynthesis
PMC - PMC5428871
EDAT- 2017/04/28 06:00
MHDA- 2018/02/21 06:00
PMCR- 2017/03/16
CRDT- 2017/04/28 06:00
PHST- 2016/08/22 00:00 [received]
PHST- 2016/11/29 00:00 [accepted]
PHST- 2017/04/28 06:00 [pubmed]
PHST- 2018/02/21 06:00 [medline]
PHST- 2017/04/28 06:00 [entrez]
PHST- 2017/03/16 00:00 [pmc-release]
AID - mmr-15-05-2546 [pii]
AID - 10.3892/mmr.2017.6339 [doi]
PST - ppublish
SO  - Mol Med Rep. 2017 May;15(5):2546-2550. doi: 10.3892/mmr.2017.6339. Epub 2017 Mar 
      16.